T1	Participants 77 132	hyperphosphatemic patients with end-stage renal disease
T2	Participants 193 241	patients receiving long-term dialysis treatment.
T3	Participants 377 422	patients with end-stage renal disease (ESRD).
T4	Participants 585 611	Chinese patients with ESRD
T5	Participants 749 786	male and female hemodialysis patients